Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Molecular Partners AG
  6. News
  7. Summary
    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Molecular Partners : H1 2021 Results and Corporate Update

08/26/2021 | 06:51am EDT

Custom Built Biology for Patients

H1 2021 Results and Corporate Update

August 26, 2021

Molecular Partners AG, Switzerland

(SIX: MOLN)

1

Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, including timing for the potential submission of emergency use authorization for ensovibep, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners' product candidates, the selection and development of future antiviral or other programs, and Molecular Partners' expected expenses and cash utilization for 2021 and that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into H2 2023. These statements may be identified by words such as "anticipate", "believe", "could", "expect", "intend", "may", "plan", "potential", "will", "would" and similar expressions, although not all forward-looking statements may contain these identifying words, and are based on Molecular Partners AG's current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from our expectations include our plans to develop and potentially commercialize our product candidates; our reliance on third party partners and collaborators over which we may not always have full control; our ongoing and planned clinical trials and preclinical studies for our product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and ability to achieve market acceptance of our product candidates; the potential impact of the COVID19 pandemic on our operations or clinical trials; our plans and development of any new indications for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position; our ability to identify and in-license additional product candidates; the adequacy of our cash resources and our anticipated cash utilization; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Registration Statement on Form F-1 filed with Securities and Exchange Commission (SEC) on June 14, 2021 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of

Molecular Partners' website at http://www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

2

H1 2021 Results & Corporate Update

R&D

COVID19 - Ensovibep (Novartis)

  • Phase 1 & small trial in patients completed
  • 2 pivotal trials ongoing, recruiting well
    • EMPATHY - ambulatory
    • ACTIV-3 - hospitalized
  • Activity on all viral variants of concern

Local immune agonists

  • AMG 506 / MP0310 - (FAP x 4-1BB, Amgen) weekly dosing; on track to initial read-out in H2/2021
  • MP0317 - (FAP x CD40) on track to FIH in H2/2021

AML (CD33+CD70+CD123 x CD3)

  • Triple-TAA-targetingTCE on track for candidate selection in H2/2021

OPERATIONAL

  • Team - 2 new BoD members
    • Agnete Fredriksen - founder of Vaccibody
    • Dominik Hochli - late-stage and commercial development
  • Financials
    • Listed on NASDAQ
    • Raised CHF 58 million gross proceeds
    • Strong balance sheet, funded into H2 2023
  • Abicipar
    • Molecular Partners will regain rights from AbbVie; transition and evaluation of data initiated

3

Infectious disease

Discovery

Pipeline

Oncology

Ophthalmology

CANDIDATE / FOCUS

RESEARCH

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

RIGHTS

Ensovibep (MP0420) / COVID-19

ACTIV-3 Ph 3 Hospitalized

Ensovibep (MP0420) / COVID-19

EMPATHY Ph 2-3 Ambulatory

Next Gen / COVID-19*

AMG 506 (MP0310) / FAP x 4-1BB

MP0317 / FAP x CD40

AML CD3 x CD33 + CD70 + CD123

Abicipar

Platform Discovery

T cell Engagers

Additional Infectious Diseases

4

Pipeline

Infectious disease Discovery

OncologyOphthalmology

No active immune engagement; improving chances of success

Rapid test and rapid treat, single-shot solution

MP0423 ready for IND as needed. Currently developing the next-gen COVID DARPin for future needs Weekly dosing, initial results H2 2021 FIH expected H2 2021 Candidate to be announced H2 2021; FIH expected 2022

Molecular Partners to regain rights to abicipar; will analyze improvements done and data collected to consider

best path forward

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Molecular Partners AG published this content on 26 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2021 10:50:08 UTC.


ę Publicnow 2021
All news about MOLECULAR PARTNERS AG
10/20MOLECULAR PARTNERS : Pre-clinical data of ensovibep, a multi-specific DARPin therapeutic w..
PU
10/20MOLECULAR PARTNERS : Says Drug Prevents Infection from COVID-19 Variants
MT
10/20MOLECULAR PARTNERS : Says Preclinical Data Show Ensovibep's Potency Against COVID-19 Viral..
MT
10/20MOLECULAR PARTNERS : Present Data Demonstrating Successful Inhibition of COVID19 Viral Var..
AQ
10/01ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
09/14Certain Common Shares of Molecular Partners AG are subject to a Lock-Up Agreement Endin..
CI
09/14Certain Options of Molecular Partners AG are subject to a Lock-Up Agreement Ending on 1..
CI
09/14Certain Restricted Share Units of Molecular Partners AG are subject to a Lock-Up Agreem..
CI
09/14Certain Performance Share Units of Molecular Partners AG are subject to a Lock-Up Agree..
CI
09/10MOLECULAR PARTNERS : MP Corporate Presentation
PU
More news
Analyst Recommendations on MOLECULAR PARTNERS AG
More recommendations
Financials
Sales 2021 52,5 M 57,0 M 57,0 M
Net income 2021 -16,2 M -17,6 M -17,6 M
Net cash 2021 119 M 130 M 130 M
P/E ratio 2021 -31,0x
Yield 2021 -
Capitalization 570 M 620 M 619 M
EV / Sales 2021 8,59x
EV / Sales 2022 7,56x
Nbr of Employees 158
Free-Float 77,5%
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 17,66 CHF
Average target price 27,41 CHF
Spread / Average Target 55,2%
EPS Revisions
Managers and Directors
Patrick Amstutz Chief Executive Officer & Director
Andreas Emmenegger Chief Financial Officer
William Matt Burns Chairman
Daniel Steiner Senior Vice President-Research
Nicolas Leupin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MOLECULAR PARTNERS AG-14.89%620
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992